Eurofins Scientific SE

Eurofins Scientific SE bought back 100,000 of its own shares between August 3 and August 7, 2026, at a daily volume of 20,000 shares each day. The daily weighted average purchase prices ranged from 68.4085 euros to 70.3102 euros, with an overall average of 69.3844 euros. All transactions were executed on the XPAR market.

Eurofins Scientific repurchased a total of 85,000 of its own shares between July 20 and July 24, 2026, at a daily weighted average purchase price of 68.3251 euros. The transactions were executed across the XPAR and CEUX markets, with daily volumes ranging from 3,180 to 20,000 shares. The highest daily average price was 70.8332 euros on July 20, while the lowest was 66.1178 euros on July 24. A full breakdown of individual trades is available on the company's website in accordance with the Market Abuse Regulation.

Eurofins Scientific posted a 29% year-on-year increase in earnings per share for the first half of 2026, alongside an adjusted EBITDA margin of 23.7% that exceeded its own objectives. Reported EBITDA margin reached 23.3%, a 190 basis point improvement, while free cash flow surged 46% to EUR 403 million, driving cash conversion to a record 47%. Organic growth came in at 2.7%, held back by a 2.9% foreign-exchange headwind and softness in biopharma, though the rest of the world delivered 9% organic revenue growth. The company also executed EUR 200 million in share buybacks, kept leverage stable at 2.2 times, and saw margin gains of 210 basis points in Europe and 230 basis points in North America excluding one-time items.

The global cell-based assay services for preclinical use only market reached approximately $4.47 billion in 2025 and is projected to grow to $12.93 billion by 2035, according to a new report from ResearchAndMarkets.com. The market recorded a compound annual growth rate of 12.3% from 2020 and is forecast to expand at 11.5% through 2030 before reaching the 2035 figure. Cytotoxicity assays were the largest segment in 2025, accounting for 30.8% of the market, while phenotypic and morphological assays are expected to be the fastest-growing category through 2030. North America led regional revenue with a 40.1% share in 2025, but Asia-Pacific is forecast to be the fastest-growing region with a 15.2% CAGR through 2030. Leading companies profiled include Charles River Laboratories, Labcorp Drug Development, Eurofins Scientific, and Evotec, with the top 10 competitors holding 19.17% of the market in 2024.

Analytical Bioventures S.C.A., a company controlled by Eurofins Scientific CEO Dr. Gilles Martin, acquired a total of 3,000 shares of Eurofins Scientific across three transactions on the Euronext Paris exchange. The purchases were made on June 25 at EUR 67.7737 per share, June 26 at EUR 68.4577 per share, and June 29 at EUR 68.4011 per share, for an aggregated total of EUR 204,632.50. The notifications were made in accordance with the European Market Abuse Regulation.

Eurofins Scientific repurchased a total of 130,000 of its own shares between 22 June and 26 June 2026, at a daily volume-weighted average price of €65.7977. The buybacks were executed across the XPAR and CEUX markets, with daily volumes ranging from 25,000 to 30,000 shares and average daily prices rising from about €62.73 on 22 June to €68.45 on 26 June. A full breakdown of individual trades is available on the company’s website in accordance with the EU Market Abuse Regulation.

Analytical Bioventures S.C.A, a company controlled by Eurofins Scientific S.E. CEO Dr. Gilles Martin, has acquired a total of 6,000 shares of Eurofins Scientific S.E. across three separate transactions. The purchases were made on June 17, 18, and 19, 2026, each for 2,000 shares at prices of EUR 62.27000, EUR 62.1825, and EUR 62.746 respectively, resulting in a total investment of EUR 374,289.00. All transactions took place on the XPAR venue and were disclosed in accordance with the European Market Abuse Regulation.